구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | omega-3-acid ethyl esters (omega-3-acid ethyl esters) ImmunityBio, Inc.·Merkel Cell Carcinoma 60 trials |
|---|---|
Overview Program | omega-3-acid ethyl esters |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | Merkel Cell Carcinoma |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Safety update: omega-3-acid ethyl esters and atrial fibrillation.. Overview of: Medicines and Healthcare products Regulatory Agency. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors. Drug Safety Update 2024;17(6):3. Comparison of Omega-3 pol… |
Clinical Safety signal | Safety update: omega-3-acid ethyl esters and atrial fibrillation.. Overview of: Medicines and Healthcare products Regulatory Agency. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors. Drug Safety Update 2024;17(6):3. Comparison of Omega-3 pol… |
Clinical Result source | ClinicalTrials.gov NCT02370537 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02370537 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | omega-3-acid ethyl esters (omega-3-acid ethyl esters) ImmunityBio, Inc.·Merkel Cell Carcinoma 60 trials |
|---|---|
Overview Program | omega-3-acid ethyl esters |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | Merkel Cell Carcinoma |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Safety update: omega-3-acid ethyl esters and atrial fibrillation.. Overview of: Medicines and Healthcare products Regulatory Agency. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors. Drug Safety Update 2024;17(6):3. Comparison of Omega-3 pol… |
Clinical Safety signal | Safety update: omega-3-acid ethyl esters and atrial fibrillation.. Overview of: Medicines and Healthcare products Regulatory Agency. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors. Drug Safety Update 2024;17(6):3. Comparison of Omega-3 pol… |
Clinical Result source | ClinicalTrials.gov NCT02370537 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02370537 |
추천 비교
추천 비교